Technical Analysis for MIRM - Mirum Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 3.56% | |
| Calm After Storm | Range Contraction | 3.56% | |
| Inside Day | Range Contraction | 3.56% | |
| 20 DMA Support | Bullish | 5.24% | |
| Upper Bollinger Band Walk | Strength | 5.24% | |
| Slingshot Bullish | Bullish Swing Setup | -2.04% | |
| Upper Bollinger Band Walk | Strength | -2.04% | |
| Upper Bollinger Band Touch | Strength | -2.04% | |
| New 52 Week Closing High | Bullish | -5.77% | |
| Expansion Breakout | Bullish Swing Setup | -5.77% |
| Alert | Time |
|---|---|
| Up 3% | about 22 hours ago |
| Non-ADX 1,2,3,4 Pullback Entry | about 23 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| Rose Above 10 DMA | about 23 hours ago |
| Up 2% | about 23 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 48.89 |
| 52 Week Low | 23.14 |
| Average Volume | 389,509 |
| 200-Day Moving Average | 33.49 |
| 50-Day Moving Average | 40.17 |
| 20-Day Moving Average | 41.30 |
| 10-Day Moving Average | 42.89 |
| Average True Range | 2.20 |
| RSI (14) | 58.51 |
| ADX | 21.46 |
| +DI | 31.90 |
| -DI | 16.72 |
| Chandelier Exit (Long, 3 ATRs) | 42.30 |
| Chandelier Exit (Short, 3 ATRs) | 44.74 |
| Upper Bollinger Bands | 45.35 |
| Lower Bollinger Band | 37.26 |
| Percent B (%b) | 0.8 |
| BandWidth | 19.59 |
| MACD Line | 1.01 |
| MACD Signal Line | 0.83 |
| MACD Histogram | 0.1804 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 47.77 | ||||
| Resistance 3 (R3) | 47.46 | 45.79 | 47.09 | ||
| Resistance 2 (R2) | 45.79 | 44.75 | 45.95 | 46.86 | |
| Resistance 1 (R1) | 44.74 | 44.11 | 45.27 | 45.05 | 46.64 |
| Pivot Point | 43.07 | 43.07 | 43.33 | 43.23 | 43.07 |
| Support 1 (S1) | 42.02 | 42.03 | 42.55 | 42.33 | 40.74 |
| Support 2 (S2) | 40.35 | 41.39 | 40.51 | 40.52 | |
| Support 3 (S3) | 39.30 | 40.35 | 40.29 | ||
| Support 4 (S4) | 39.61 |
